Corporate Profile for Syrrx Inc., dated Feb. 28, 2003.Business Editors --(BUSINESS WIRE) The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.
Published Date: Feb. 28, 2003
Company Name: Syrrx Inc.
Address: 10410 Science Center Drive
San Diego, Calif. 92121
Main Telephone
Number: 858/622-8528
Internet Home
Page Address
(URL) www.syrrx.com
Chief Executive
Officer: Wendell Wierenga, Ph.D.
Chief Financial
Officer: Norman Halleen
Investor Relations
Contact: Norman Halleen
Business number: 858/731-3512
E-mail address: norman.halleen@syrrx.com
Public Relations
Contact: Sofie Qiao, Ph.D.
Business number: 858/622-8528
E-mail address: sofie.qiao@syrrx.com
Industry: Biotechnology
Company description: Syrrx Inc. is a drug discovery company redefining the way medicines are discovered. Based in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , the company is at the forefront of high-throughput rational drug discovery and is currently directing its efforts toward developing therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. in oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. , inflammation and metabolic diseases metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome . Syrrx intends to leverage high-throughput structure determination, screening, combinatorial and medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. together with computational Having to do with calculations. Something that is "highly computational" requires a large number of calculations. methods to discover novel small molecule drug candidates. In combination, these proprietary technologies form a unique "gene to drug" platform that should enable high-throughput rational drug discovery. Syrrx has structural proteomic and drug discovery collaborations with industry leaders, including Sankyo Co. Ltd., Hoffman-La Roche Ltd., Pharmacia Corp., Celera Genomics Group and Cubist Pharmaceuticals. The company has also acquired small molecule assets from Onyx onyx (ŏn`ĭks), variety of cryptocrystalline quartz, differing from agate only in that the bands of which it is composed are parallel and regular. Pharmaceuticals for use in the internal discovery programs at Syrrx. For more information, please visit the Syrrx Web site at http://www.syrrx.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion